Your search found 9 Results
Lancet. 1992 Mar 28; 339(8796):783-4.It is difficult to determine if the IUD increases the risk of pelvic inflammatory disease (PID) because simple clinical features are not consistently predictive and can have low specificity and sensitivity. The C-reactive protein and the erythrocyte sedimentation rate tests help with PID diagnosis, but only a laparoscopy can determine tubal involvement. In 1970, WHO's Cooperative Statistical Programme found 2-year combined PID rates to range from 3.8 to 5.2/100 women with an IUD. Then WHO and various US organizations agreed IUD use did not necessarily cause PID. During the 1970s, however, a large rise in sexually transmitted diseases (STDs), especially chlamydia and gonorrhea, occurred and were associated with PID incidence. Many believed the growing rate of PID was attributable to the increasing use of IUDs. Many studies were biased because of overdiagnosis of PID. A 1990 review of 28 articles revealed that the overall PID rate was 1.49/100 woman years (lower than what many believed earlier). Some researchers used multicountry data on 22, 908 IUD insertions from WHO's data base for IUD studies to determine PID risk in IUD users. This risk was somewhat high during the 1st 20 days postinsertion which may be related to insertion, but PID rates in IUD users corresponded with those from the general population. PID rates did increase with age, however, and they did vary with geographical area. In addition, rates were 62% lower in women whose IUD was inserted after 1980. The PID rate was associated with background risk of STDs. These results and those of other studies suggest that health staff must adequately assess all patients before fitting the IUD and insert it only under strict aseptic conditions. IUDs that release copper and levonorgestrel pose a lower risk of PID than nonmedicated IUDs.
Ippf Medical Bulletin. 1986 Apr; 20(2):1.This statement sets forth the views of the International Planned Parenthood Federation's (IPPF) International Medical Advisory Panel (IMAP) on the safety of IUD use. There has been concern about the recent withdrawal from the US market by Ortho Pharmaceuticals and GD Searle & Co. of 3 widely used IUDs: Lippes Loop, Copper 7, and Copper T200. It is noted that these actions were taken for commercial reasons related to profitability and/or liability insurance concerns, and not for medical or scientific reasons. The 3 IUDs that were withdrawn from the USmarket continue to be approved for contraceptive use by the US Food and Drug Administration. After extensive review of available data, IMAP at its London meeting in February 1986, reaffirmed its earlier position on the IUD, supporting it as a safe and effective method of contraception. Although concern has been expressed about potential increases in the risks of pelvic inflammatory disease and tubal infertility as a result of IUD use, recent research suggests that women who use copper-bearing devices, particularly married women in primarily monogamous relationships, are a relatively low risk. On the other hand, women with multiple partners, especially nulliparous women, who are already at risk of sexually transmitted diseases, are not good candidates for IUD use. IPPF will continue to provide IUDs upon request to its member associations.
In: Santamaria J, Richards P, Gibbon W, eds. The dignity of man and creative love: selected papers from the Congress for the family of the Americas, Guatemala, July 1980. New Haven, Connecticut, Knights of Columbus, 1980. 188-95.The USAID (U.S. Agency for International Development) has since 1960 promoted abortion worldwide, without concern for the laws, customs, or mores of foreign lands. USAID still promotes the sale and the use of Depo-Provera in Latin America. Depo-Provera, a drug that acts as a contraceptive and abortifacient, is considered by the U.S. Food and Drug Administration to be unsafe for birth control in the U.S. USAID also promotes the sale and the use of the Dalkon Shield type of IUD, which was recalled in the U.S. in 1975 for its hazardous side effects. Moreover, USAID supports abortion research worldwide; for example, there are 3 main USAID funded university research projects in the U.S., beside the London-Based IPPF, and the Boston-based Pathfinder Fund. It is about time that the American people, and the Prolife movement in particular, realize USAID's abortion activities, and act to have Congress pass the Helms Amendment of 1973, which intented to rid USAID of any involvement in abortion related activities.
IPPF Medical Bulletin. 1980 Dec; 14(6):3.The Dalkon Shield IUD was introduced to the list of contraceptives being distributed to developing countries by IPPF (International Planned Parenthood Federation) in 1973. By 1974, doubts had arisen about the safety of the Dalkon Shield and several cases of maternal mortality and sepsis in Dalkon Shield users had been reported. In 1974, IPPF stopped supplying Dalkon Shields to its affiliates. During the 1973-74 period of distribution, IPPF had distributed approximately 300,000 of the Shields in 41 countries. Almost 1/2 that amount had already been inserted. The position of IPPF's IMAP (International Medical Advisory Panel) on any relationship existing between use of IUDs and pelvic inflammatory disease is as follows as of 1980: 1) infection with actinomycosis makes up only a small component of all the incidents of pelvic inflammatory disease connected with IUDs; 2) the occurrence of pelvic inflammatory disease is not related to the length of use of an IUD; 3) data do not now support the recommendation that inert devices free from major side effects should be removed; and 4) any woman still wearing a Dalkon Shield should have it removed.
International Family Planning Perspectives. 1979 Sep; 5(3):127-9.The International Fertility Research Program (IFRP) is sponsoring research in 30 developing countries and 13 developed nations in an effort to develop more effective contraceptive methods. Particular emphasis is being placed on developing contraceptives for women in developing countries where nutritional, health, and sanitation conditions make current methods either difficult or less effective to use. Trials of a pill regimen including vitamin supplementation are underway in Sri Lanka, and a progestogen-only pill for use by lactating women is being tested in Egypt and India. Progestogens apparently do not modify the content of maternal milk. Another study involves the testing of a Lippes loop which releases Trasylol, a bleeding suppressant, in an effort to overcome bleeding problems associated with IUD use. The IFRP has developed and is testing biodegradable appendages which can be attached to IUDs to help retain the device in postpartum women during the period when the uterus is enlarged. Other efforts are being directed toward improving and simplifying sterilization procedures. In Chile, pellets of quinacrine have been inserted into the upper area of the uterus. As the pellets dissolve the quinacrine enters the tubes and produces scar tissue which eventually closes the tube. This research may pave the way toward the development of a non-surgical sterilization method. Animal studies of a reversible sterilization procedure in which a condom-like device is fitted over the ends of the tubes are in progress. In another project a modified laparoscope, called the Laprocator, is being evaluated. The device does not use electricity and is particularly suitable for use in areas in which electricity is lacking or the source is unstable. The device is used in a procedure called suprapubic endoscopy in which only a small incision is needed. Insufflation of the abdomen is unnecessary, and elastic rings are used to close the tubes. IFRP will undertake an innovative motivational project in the Middle East during the coming religious holidays.
[Unpublished] 1979. 6 p.The 2 primary IUDs distributed by IPPF have been the Saf-T-Coil and Lippes Loop. Since 1976 they have also supplied the Copper T. They are currently considering use of the Soonawalla Y and the Nova T, which is similar to the Copper T. The Copper Ts distributed were: in 1976, 37,200; in 1977, 58,200; in 1978, 22,780; and in 1979, 156,9000 to date. Latin American countries have received the largest shipments. Chile received 5000 in 1978, 58,000 in 1979. Colombia received 500 in 1976, 25,000 in 1977, and 60,000 in 1979. Other countries receiving 5000 or more in any 1 year are Pakistan (5000/1976), India (10,000/1977), Egypt (5000/1979), Barbados (5000/1976), Costa Rica (7000/1977), and Ecuador (5000/1977). A complete listing of IUDs supplied to specific countries is attached.
Personal communication. 1979 Mar 23; 12.Tables show total purchases direct from manufacturers, in quantities and dollar values, of IUDs, condoms, injectables, and spermicides, out of UNFPA, WHO, Population Council, IPPF, and UNICEF Funds for individuals years from 1974 to 1978 for 40 countries in Africa, Asia, and Latin America. Th 2 types of IUDs that were mainly purchased were the Lippes Loop and the CuT200, both of which are aggregated into a single figure. Figures are given both for total value of purchases, total amounts purchased, and reimbursable procurement.
In: United States. Congress. House. Committee on Interstate and Foreign Commerce. Subcommittee on Health and the Environment. Medical device amendments of 1975. Hearings...94th Congress, 1st session on H.R.5545...H.R.974...and S.510., July 28, 29, 30, and 31, 1975. Washington, D.C., U.S. Government Printing Office, 1975. p. 482-485A request for federal legislation governing regulation and surveillance of medical devices, spcifically IUDs, to protect the public against the dangers of unsafe, ineffective, or misrepresented contraceptives was put forward by a representative of the Planned Parenthood Federation of America (PPFA). The medical policies and the role in delivery of family planning health care for the PPFA is described. In consideration of the choice of IUD as a contraceptive method, contraindications are considered, follow-up scheduled, and patient information issued to ensure the effective and safe use of the method. The recent experience with the Dalkon shield underscores the need for placing strong statutory authority with the Food and Drug Administration to evaluate and regulate all IUDs prior to marketing. The right to choose the number and spacing of one's children is a basic human right. The federal government must adopt a program of subsidized family planning services and scientific research to develop new, safer, more varied means of effective contraception.
IPPF Situation Report, February 1974. 10 p.The Planned Parenthood Federation of Korea (PPFK) was founded in 196 1 to act as a pressure group to persuade the government to set up a family planning program. In 1962 the Korean government became 1 of the 1st in the world with such an official program. PPFK has a permanent staff of 62 at headquarters and 135 at branch offices to implement the information/education program. It was formerly responsible for the training for the government effort and it continues to initiate research and pilot projects. It also indirectly supports the clincs at Seoul National University and Yonsei University Medical colleges, runs 14 demonstration clincs, and has a mobile team unit in Taegi City and surrounding rural areas. Since 1968 it has organized "Mothers' Classes" which have been integrated into the rural community development program. Special projects include a "Stop at 2" campaign which the government officially adopted. The "Two Child Family" club was started in Seoul in 1971 and is expanding. UNFPA is funding an information, education, and communication campaign that will explore various uses of mass media. Pilot telephone consultation was begun in 1973. Vasectomy information is being given to the Homeland Reserve Force, an education project has been started for civil servants, and student newspapers are being used to reach the student population. PPFK has national responsib ility for clinical trials of new contraceptives. Tests on Minovlar ED continue and the results of Neovlar trials are being analyzed. Details of the government organizations are given. Research being carried on at various universities and in other agencies is also capsuled.